AL-8810
Based on 2 publication(s) in Google Scholar
AL-8810 is a potent and selective antagonist of the PGF 2α receptor (FP receptor). AL-8810 is an activator of MAPK and ERK1/2. The Ki of the FP receptor of mouse 3T3 cells and rat A7r5 cells are 0.2±0.06 μM and 0.4±0.1 μM, respectively. AL-8810 can be used in the study of elevated intraocular pressure (OHT) and primary open-angle glaucoma (POAG).
For research use only. We do not sell to patients.
- Purity: 99.0%
- CAS No.: 246246-19-5
- Formula: C24H31FO4
- Molecular Weight:402.50
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) AL-8810
More
Biological Activity
AL-8810 (0.1, 1, 10 μM, 24 h) can significantly reduce the neuronal cell death of WT mice after OGD-induced injury[2].
AL-8810 (1, 10 μM, 24 h) promotes the activation of ERK1/2 in HEK 293 and MG-63 cells through epidermal growth factor receptor deactivation mechanism[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK 293, MG-63
-
Concentration:1, 10 μM
-
Incubation Time:24 h
-
Result:Activated ERK1/2 and MAPK. Activated MAPK through EGFR transactivation.
AL-8810 (10 mg/kg, intraperitoneal injection) can improve the prognosis after experimental traumatic brain injury in mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Stroke mouse model[2]
-
Dosage:1 or 10 mg/kg
-
Administration:i.v.
-
Result:Reduced the cortical infarct volume and tape-removal times.
-
Animal Model:Traumatic brain injury (TBI) model[5]
-
Dosage:10 mg/kg
-
Administration:i.p.
-
Result:Improved neurological deficit scores (NDS) at 24 and 48 hours after controlled cortical impact (CCI).
Chemical Information
-
CAS No. 246246-19-5
-
Appearance Solid
-
Molecular Weight 402.50
-
Formula C24H31FO4
-
Color White to off-white
-
SMILES
O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](C2CC3=C(C=CC=C3)C2)O)[C@@H](F)C[C@@H]1O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Pathol Res Pract
Prostaglandin F2α impairs skin regeneration via FP receptor-mediated oxidative stress overriding autophagic protection in fibroblasts. [Abstract]2026 Jun:282:156467. PMID: 41985369 -
Mol Cell Endocrinol
Embryo-derived human chorionic gonadotropin promotes human decidualization through activating epithelial prostaglandin F2α secretion. [Abstract]2025 Sep 1:606:112581. PMID: 40398806
Solvent & Solubility
DMSO : ≥ 10 mg/mL (24.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Griffin BW, et al. AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther. 1999 Sep;290(3):1278-84. [Content Brief]
[2]. Kim YT, et al. Prostaglandin FP receptor inhibitor reduces ischemic brain damage and neurotoxicity. Neurobiol Dis. 2012 Oct;48(1):58-65. doi: 10.1016/j.nbd.2012.06.003. Epub 2012 Jun 16. [Content Brief]
[3]. Goupil E, et al. Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK. Mol Endocrinol. 2012 Jul;26(7):1189-202. [Content Brief]
[4]. Sharif NA, et al. Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility. Br J Pharmacol. 2019 Apr;176(8):1059-1078. [Content Brief]
[5]. Glushakov AV, et al. Prostaglandin F2α FP receptor antagonist improves outcomes after experimental traumatic brain injury. J Neuroinflammation. 2013 Oct 30;10:132. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4845 mL | 12.4224 mL | 24.8447 mL | 62.1118 mL |
| 5 mM | 0.4969 mL | 2.4845 mL | 4.9689 mL | 12.4224 mL | |
| 10 mM | 0.2484 mL | 1.2422 mL | 2.4845 mL | 6.2112 mL | |
| 15 mM | 0.1656 mL | 0.8282 mL | 1.6563 mL | 4.1408 mL | |
| 20 mM | 0.1242 mL | 0.6211 mL | 1.2422 mL | 3.1056 mL |